Attached files
file | filename |
---|---|
EX-31.2 - EXHIBIT 31.2 - KMG CHEMICALS INC | c18549exv31w2.htm |
EX-32.1 - EXHIBIT 32.1 - KMG CHEMICALS INC | c18549exv32w1.htm |
EX-32.2 - EXHIBIT 32.2 - KMG CHEMICALS INC | c18549exv32w2.htm |
EX-31.1 - EXHIBIT 31.1 - KMG CHEMICALS INC | c18549exv31w1.htm |
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
(Mark One)
þ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended April 30, 2011
or
o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to .
Commission file number: 000-29278
KMG CHEMICALS, INC.
(Exact name of registrant as specified in its charter)
Texas | 75-2640529 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |
9555 West Sam Houston Parkway South, Suite 600 | ||
Houston, Texas (Address of principal executive offices) |
77099 (Zip Code) |
(713) 600-3800
(Registrants telephone number, including area code)
(Registrants telephone number, including area code)
(Former name, former address and former fiscal year, if changed since last report)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed
by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes þ No o
Indicate by check mark whether the registrant has submitted electronically and posted on its
corporate Web site, if any, every Interactive Data File required to be submitted and posted
pursuant to Rule 405 of Regulation S-T(§232.405 of this chapter) during the preceding 12 months (or
for such shorter period that the registrant was required to submit and post such files). Yes
o No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated
filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large
accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the
Exchange Act. (Check one):
Large accelerated filer o | Accelerated filer þ | Non-accelerated filer o | Smaller reporting company o | |||
(Do not check if a smaller reporting company) |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of
the Exchange Act). Yes o No þ
As of June 9, 2011, there were 11,318,941 shares of the registrants common stock outstanding.
TABLE OF CONTENTS
3 | ||||||||
3 | ||||||||
4 | ||||||||
5 | ||||||||
6 | ||||||||
15 | ||||||||
21 | ||||||||
21 | ||||||||
22 | ||||||||
22 | ||||||||
22 | ||||||||
22 | ||||||||
22 | ||||||||
22 | ||||||||
22 | ||||||||
23 | ||||||||
Exhibit 31.1 | ||||||||
Exhibit 31.2 | ||||||||
Exhibit 32.1 | ||||||||
Exhibit 32.2 |
2
Table of Contents
PART I FINANCIAL INFORMATION
ITEM 1. | FINANCIAL STATEMENTS |
KMG CHEMICALS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands except for share and per share data)
April 30, | July 31, | |||||||
2011 | 2010 | |||||||
(Unaudited) | ||||||||
ASSETS |
||||||||
CURRENT ASSETS: |
||||||||
Cash and cash equivalents |
$ | 927 | $ | 4,728 | ||||
Accounts receivable: |
||||||||
Trade, net of allowances of $242 at April 30, 2011 and $260 at July 31, 2010 |
32,023 | 30,214 | ||||||
Other |
3,754 | 2,864 | ||||||
Inventories, net |
41,343 | 39,102 | ||||||
Current deferred tax assets |
811 | 672 | ||||||
Prepaid expenses and other current assets |
2,708 | 1,882 | ||||||
Total current assets |
81,566 | 79,462 | ||||||
PROPERTY, PLANT AND EQUIPMENT, net |
71,449 | 68,645 | ||||||
DEFERRED TAX ASSETS |
1,105 | 606 | ||||||
GOODWILL |
3,778 | 3,778 | ||||||
INTANGIBLE ASSETS, net |
19,721 | 20,534 | ||||||
RESTRICTED CASH |
| 189 | ||||||
OTHER ASSETS, net |
3,114 | 2,807 | ||||||
TOTAL ASSETS |
$ | 180,733 | $ | 176,021 | ||||
LIABILITIES & STOCKHOLDERS EQUITY |
||||||||
CURRENT LIABILITIES: |
||||||||
Accounts payable |
$ | 21,677 | $ | 20,899 | ||||
Accrued liabilities |
6,196 | 7,147 | ||||||
Current deferred tax liabilities |
28 | 28 | ||||||
Current portion of long-term debt |
8,000 | 8,000 | ||||||
Total current liabilities |
35,901 | 36,074 | ||||||
LONG-TERM DEBT, net of current portion |
43,240 | 51,333 | ||||||
DEFERRED TAX LIABILITIES |
3,811 | 2,644 | ||||||
OTHER LONG-TERM LIABILITIES |
1,310 | 1,192 | ||||||
Total liabilities |
84,262 | 91,243 | ||||||
COMMITMENTS AND CONTINGENCIES |
||||||||
STOCKHOLDERS EQUITY |
||||||||
Preferred stock, $.01 par value, 10,000,000 shares authorized, none issued |
| | ||||||
Common stock, $.01 par value, 40,000,000 shares authorized, 11,313,991 shares
issued and outstanding at April 30, 2011 and 11,229,487 shares issued and
outstanding at July 31, 2010 |
113 | 112 | ||||||
Additional paid-in capital |
25,148 | 24,319 | ||||||
Accumulated other comprehensive loss |
(285 | ) | (3,335 | ) | ||||
Retained earnings |
71,495 | 63,682 | ||||||
Total stockholders equity |
96,471 | 84,778 | ||||||
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY |
$ | 180,733 | $ | 176,021 | ||||
See notes to condensed consolidated financial statements.
3
Table of Contents
KMG CHEMICALS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
(in thousands except for per share data)
Three Months Ended | Nine Months Ended | |||||||||||||||
April 30, | April 30, | |||||||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||||||
NET SALES |
$ | 65,074 | $ | 51,614 | $ | 192,114 | $ | 146,162 | ||||||||
COST OF SALES |
47,320 | 35,658 | 138,726 | 95,103 | ||||||||||||
Gross Profit |
17,754 | 15,956 | 53,388 | 51,059 | ||||||||||||
DISTRIBUTION EXPENSES |
7,599 | 4,762 | 21,322 | 14,139 | ||||||||||||
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES |
5,572 | 5,362 | 17,117 | 16,214 | ||||||||||||
Operating income |
4,583 | 5,832 | 14,949 | 20,706 | ||||||||||||
OTHER INCOME (EXPENSE): |
||||||||||||||||
Interest income |
| 3 | 1 | 5 | ||||||||||||
Interest expense |
(571 | ) | (542 | ) | (1,765 | ) | (1,634 | ) | ||||||||
Other, net |
50 | (69 | ) | (140 | ) | (168 | ) | |||||||||
Total other expense, net |
(521 | ) | (608 | ) | (1,904 | ) | (1,797 | ) | ||||||||
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES |
4,062 | 5,224 | 13,045 | 18,909 | ||||||||||||
Provision for income taxes |
(1,411 | ) | (1,882 | ) | (4,418 | ) | (6,984 | ) | ||||||||
INCOME FROM CONTINUING OPERATIONS |
2,651 | 3,342 | 8,627 | 11,925 | ||||||||||||
DISCONTINUED OPERATIONS: |
||||||||||||||||
Loss from discontinued operations, before income taxes |
(57 | ) | | (104 | ) | | ||||||||||
Income tax benefit |
13 | | 24 | | ||||||||||||
Loss from discontinued operations |
(44 | ) | | (80 | ) | | ||||||||||
NET INCOME |
$ | 2,607 | $ | 3,342 | $ | 8,547 | $ | 11,925 | ||||||||
EARNINGS PER SHARE: |
||||||||||||||||
Basic |
||||||||||||||||
Income from continuing operations |
$ | 0.23 | $ | 0.30 | $ | 0.76 | $ | 1.07 | ||||||||
Loss from discontinued operations |
| | (0.01 | ) | | |||||||||||
Net income |
$ | 0.23 | $ | 0.30 | $ | 0.75 | $ | 1.07 | ||||||||
Diluted |
||||||||||||||||
Income from continuing operations |
$ | 0.23 | $ | 0.29 | $ | 0.75 | $ | 1.05 | ||||||||
Loss from discontinued operations |
| | (0.01 | ) | | |||||||||||
Net income |
$ | 0.23 | $ | 0.29 | $ | 0.74 | $ | 1.05 | ||||||||
WEIGHTED AVERAGE SHARES OUTSTANDING: |
||||||||||||||||
Basic |
11,313 | 11,198 | 11,306 | 11,168 | ||||||||||||
Diluted |
11,499 | 11,436 | 11,484 | 11,410 |
See notes to condensed consolidated financial statements.
4
Table of Contents
KMG CHEMICALS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(in thousands)
Nine Months Ended | ||||||||
April 30, | ||||||||
2011 | 2010 | |||||||
CASH FLOWS FROM OPERATING ACTIVITIES: |
||||||||
Net income |
$ | 8,547 | $ | 11,925 | ||||
Adjustments to reconcile net income to net cash provided by operating activities: |
||||||||
Depreciation and amortization |
5,688 | 4,442 | ||||||
Amortization of loan costs included in interest expense |
82 | 66 | ||||||
Stock-based compensation expense |
441 | 450 | ||||||
Bad debt expense (recovery) |
(18 | ) | 166 | |||||
Inventory valuation adjustment |
(138 | ) | (4 | ) | ||||
Loss on disposal of property |
131 | | ||||||
Deferred income tax expense |
546 | 806 | ||||||
Tax benefit from stock-based awards |
(196 | ) | (331 | ) | ||||
Changes in operating assets and liabilities, net of effects of acquisition |
||||||||
Accounts receivable trade |
(1,128 | ) | (5,648 | ) | ||||
Accounts receivable other |
(676 | ) | (225 | ) | ||||
Inventories |
(1,598 | ) | 202 | |||||
Prepaid expenses and other assets |
(1,127 | ) | (728 | ) | ||||
Accounts payable |
452 | 376 | ||||||
Accrued liabilities |
(1,034 | ) | (1,329 | ) | ||||
Net cash provided by operating activities |
9,972 | 10,168 | ||||||
CASH FLOWS FROM INVESTING ACTIVITIES: |
||||||||
Additions to property, plant and equipment |
(5,809 | ) | (1,233 | ) | ||||
Proceeds from sale of property |
59 | | ||||||
Cash used in connection with General Chemical acquisition |
| (26,744 | ) | |||||
Change in restricted cash |
189 | 109 | ||||||
Net cash used in investing activities |
(5,561 | ) | (27,868 | ) | ||||
CASH FLOWS FROM FINANCING ACTIVITIES: |
||||||||
Net borrowings (payments) under revolver credit agreement |
(2,093 | ) | 20,000 | |||||
Principal payments on borrowings on term loan |
(6,000 | ) | (4,958 | ) | ||||
Proceeds from exercise of stock options |
200 | 138 | ||||||
Tax benefit from stock-based awards |
196 | 331 | ||||||
Payment of dividends |
(735 | ) | (669 | ) | ||||
Net cash (used in) provided by financing activities |
(8,432 | ) | 14,842 | |||||
EFFECT OF EXCHANGE RATE CHANGES ON CASH |
220 | (217 | ) | |||||
NET DECREASE IN CASH AND CASH EQUIVALENTS |
(3,801 | ) | (3,075 | ) | ||||
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD |
4,728 | 7,174 | ||||||
CASH AND CASH EQUIVALENTS AT END OF PERIOD |
$ | 927 | $ | 4,099 | ||||
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: |
||||||||
Cash paid for interest |
$ | 1,746 | $ | 1,550 | ||||
Cash paid for income taxes |
$ | 3,748 | $ | 7,633 |
See notes to condensed consolidated financial statements.
5
Table of Contents
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(1) Basis of Presentation.
The (a) consolidated balance sheet as of July 31, 2010, which has
been derived from audited consolidated financial statements, and (b) the unaudited condensed
consolidated financial statements included herein have been prepared pursuant to the rules and
regulations of the Securities and Exchange Commission for interim reporting. As permitted under
those requirements, certain footnotes or other financial information that are normally required by
generally accepted accounting principles in the United States of America (GAAP) have been
condensed or omitted. The Company believes that the disclosures made are adequate to make the
information not misleading and in the opinion of management reflect all adjustments, including
those of a normal recurring nature, that are necessary for a fair presentation of financial
position and results of operations for the interim periods presented. The results of operations for
the interim periods are not necessarily indicative of results of operations to be expected for the
full year. The unaudited condensed consolidated financial statements included herein should be read
in conjunction with the consolidated financial statements and notes thereto included in the
Companys Annual Report on Form 10-K for the year ended July 31, 2010.
These condensed consolidated financial statements are prepared using certain estimates by
management and include the accounts of KMG Chemicals, Inc. and its subsidiaries (collectively, the
Company). All significant intercompany balances and transactions have been eliminated in
consolidation. Certain reclassifications have been made to the prior period consolidated financial
statements to conform to the current period presentation.
During the second quarter of fiscal year 2011, the Company changed its estimate of the useful
lives of certain equipment purchased in the General Chemical acquisition. This change had the
effect of decreasing depreciation expense by $350,000, and the effect of increasing income from
continuing operations before income taxes by $350,000, increasing net income by $215,000 and increasing basic and
diluted earnings per share by $0.02 for the three month period ended April 30, 2011. For the nine
month period ended April 30, 2011, this change had the effect of decreasing depreciation expense by
$761,000, and the effect of increasing income from continuing
operations before income taxes by $761,000, increasing
net income by $470,000 and increasing basic and diluted earnings per share by $0.04.
(2) Acquisition.
On March 29, 2010, the Company acquired certain assets of the electronic
chemicals business of General Chemical Performance Products, LLC (General Chemical). The acquired
business included products similar to the products of the Companys existing electronic chemicals
business. The purpose of the acquisition was to expand the Companys manufacturing capability and
increase market share.
The purchase included inventory, a 48,000 square foot manufacturing facility in Hollister,
California and certain equipment at General Chemicals Bay Point, California facility. The Company
additionally entered into a manufacturing agreement with General Chemical under which they will
continue to manufacture certain acid products at their Bay Point facility, using the equipment at
the facility which was purchased by the Company. The Company paid $26.8 million in cash for the
acquisition which was financed with available cash and borrowings under the Companys revolving
credit facility.
The following table summarizes the consideration paid for the acquired assets and the
acquisition accounting for the fair value of the assets recognized in the consolidated balance
sheets at the acquisition date (in thousands):
Consideration: |
||||
Cash |
$ | 26,784 | ||
Fair value of identifiable assets acquired: |
||||
Inventory, net of allowance |
$ | 7,604 | ||
Property, plant and equipment |
17,706 | |||
Intangible assets: |
||||
Value of product qualifications |
1,300 | |||
Non-compete agreement |
150 | |||
Total intangible assets |
1,450 | |||
Other |
24 | |||
Total identifiable assets acquired |
$ | 26,784 | ||
6
Table of Contents
The following table sets forth pro forma results for the three and nine months ended April 30,
2010 had the acquisition occurred as of the beginning of fiscal year 2009. The pro forma financial
information is not necessarily indicative of what our consolidated results of operations would have
been had we completed the acquisition as of the date indicated.
Three months ended | Nine months ended | |||||||
April 30, 2010 | April 30, 2010 | |||||||
(Unaudited) | ||||||||
(in thousands, except per share data) | ||||||||
Revenues |
$ | 58,810 | $ | 174,381 | ||||
Operating income |
6,241 | 22,642 | ||||||
Net income |
3,617 | 13,105 | ||||||
Earnings per share basic |
$ | 0.32 | $ | 1.17 |
The Company is consolidating manufacturing for its U.S.-based electronic chemicals at its
Pueblo, CO and Hollister, CA facilities. As a result it is not practicable to determine the revenue
and earnings attributable to the acquired business included in the Companys consolidated
statements of income for the reporting period.
Depreciation included in the pro forma financial information is approximately $180,000 per
month.
(3) Recent Accounting Standards.
The Company has considered all recently issued accounting
standards updates and SEC rules and interpretive releases.
In December 2010, the Financial Accounting Standards Board issued new accounting guidance for
the disclosure of supplementary pro forma information for business combinations. The guidance
clarifies the acquisition date that should be used for reporting the pro forma financial
information disclosures when comparative financial statements are presented and specifies that the
entity should disclose revenue and earnings of the combined entity as though the business
combination(s) that occurred during the current year had occurred as of the beginning of the
comparable prior annual reporting period only. The guidance also expands the supplemental pro forma
disclosure requirements to include a description of the nature and amount of material, non
recurring pro forma adjustments directly attributable to the business combination included in the
reported pro forma information. The new guidance is effective prospectively for business
combinations with an acquisition date on or after the beginning of the first annual reporting
period beginning on or after December 15, 2010. Early adoption is permitted. The Company does not
expect the new guidance to have a material impact on its consolidated financial statements.
(4) Earnings Per Share.
Basic earnings per share have been computed by dividing net income by
the weighted average shares outstanding. Diluted earnings per share have been computed by dividing
net income by the weighted average shares outstanding plus potentially dilutive common shares. The
following table presents information necessary to calculate basic and diluted earnings per share
for periods indicated:
Three Months Ended | Nine Months Ended | |||||||||||||||
April 30, | April 30, | |||||||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||||||
(Amounts in thousands, except per share data) | ||||||||||||||||
Income from continuing operations |
$ | 2,651 | $ | 3,342 | $ | 8,627 | $ | 11,925 | ||||||||
Loss from discontinued operations |
(44 | ) | | (80 | ) | | ||||||||||
Net income |
$ | 2,607 | $ | 3,342 | $ | 8,547 | $ | 11,925 | ||||||||
Weighted average shares outstanding-basic |
11,313 | 11,198 | 11,306 | 11,168 | ||||||||||||
Dilutive effect of options and stock awards |
186 | 238 | 178 | 242 | ||||||||||||
Weighted average shares outstanding-diluted |
11,499 | 11,436 | 11,484 | 11,410 | ||||||||||||
BASIC EARNINGS PER SHARE |
||||||||||||||||
Basic earnings per share from continuing operations |
$ | 0.23 | $ | 0.30 | $ | 0.76 | $ | 1.07 | ||||||||
Basic earnings per share on loss from discontinued operations |
| | (0.01 | ) | | |||||||||||
Basic earnings per share |
$ | 0.23 | $ | 0.30 | $ | 0.75 | $ | 1.07 | ||||||||
DILUTED EARNINGS PER SHARE |
||||||||||||||||
Diluted earnings per share from continuing operations |
$ | 0.23 | $ | 0.29 | $ | 0.75 | $ | 1.05 | ||||||||
Diluted earnings per share on loss from discontinued operations |
| | (0.01 | ) | | |||||||||||
Diluted earnings per share |
$ | 0.23 | $ | 0.29 | $ | 0.74 | $ | 1.05 | ||||||||
7
Table of Contents
Outstanding stock based awards are not included in the computation of diluted earnings per
share under the treasury stock method, if including them would be anti-dilutive. There were no
shares and less than 1,000 shares of potentially dilutive securities not included in the
computation of diluted earnings per share for three and nine month periods ended April 30, 2011,
respectively. There were less than 1000 shares of potentially dilutive securities not included in
the computation of diluted earnings per share for the periods ended April 30, 2010.
(5) Inventories.
Inventories are summarized in the following table (in thousands):
April 30, | July 31, | |||||||
2011 | 2010 | |||||||
Raw materials and supplies |
$ | 10,453 | $ | 8,578 | ||||
Finished products |
31,215 | 30,942 | ||||||
Less reserve for inventory obsolescence |
(325 | ) | (418 | ) | ||||
Inventories, net |
$ | 41,343 | $ | 39,102 | ||||
(6) Property, Plant and Equipment.
Property, plant and equipment and related accumulated
depreciation and amortization are summarized as follows (in thousands):
April 30, | July 31, | |||||||
2011 | 2010 | |||||||
Land |
$ | 10,399 | $ | 9,428 | ||||
Buildings & improvements |
35,677 | 34,399 | ||||||
Equipment |
43,504 | 40,195 | ||||||
Leasehold improvements |
132 | 132 | ||||||
89,712 | 84,154 | |||||||
Less accumulated depreciation and amortization |
(23,086 | ) | (18,054 | ) | ||||
66,626 | 66,100 | |||||||
Construction-in-progress |
4,823 | 2,545 | ||||||
Property, plant and equipment, net |
$ | 71,449 | $ | 68,645 | ||||
(7) Stock-Based Compensation.
The Company has stock-based incentive plans which are described
in more detail in note 11 to the consolidated financial statements in the Companys Annual Report
on Form 10-K for fiscal year 2010. The Company recognized stock-based compensation costs of
approximately $66,000 and $238,000, respectively, for the three months ended April 30, 2011 and
2010, and approximately $440,000 and $450,000 for the nine months ended April 30, 2011 and 2010,
respectively, which are recorded as selling, general and administrative expenses in the
consolidated statements of income.
As of April 30, 2011, the unrecognized compensation costs related to stock-based awards was
approximately $988,000, including $24,000 related to non-vested stock options expected to be
recognized over a weighted-average period of 1.7 years and $964,000 related to non-vested
performance and time-based stock awards expected to be recognized over a weighted-average period of
1.5 years.
A summary of stock option and stock activity is presented below.
Stock Options
A summary of activity associated with the nine months ended April 30, 2011 is presented below.
Weighted- | ||||||||
Average | ||||||||
Shares | Exercise Price | |||||||
Outstanding on August 1, 2010 |
272,000 | $ | 3.98 | |||||
Granted |
| | ||||||
Exercised |
(50,000 | ) | 4.00 | |||||
Forfeited/Expired |
| | ||||||
Outstanding on April 30, 2011 |
222,000 | 3.98 | ||||||
8
Table of Contents
The following table summarizes information about stock options outstanding at April 30, 2011
based on fully vested (currently exercisable) stock option awards and stock options awards expected
to vest:
Weighted- | ||||||||||||||||
Weighted- | Average | |||||||||||||||
Average | Remaining | Aggregate | ||||||||||||||
Options | Exercise Price | Contractual | Intrinsic Value | |||||||||||||
Outstanding | per Share | Term (years) | (in thousands) (1) | |||||||||||||
Fully vested and currently exercisable |
174,500 | $ | 3.89 | 5.5 | $ | 2,915 | ||||||||||
Expected to vest |
47,500 | 4.33 | 11.8 | 772 | ||||||||||||
Total outstanding stock options |
222,000 | 3.98 | 6.9 | $ | 3,687 | |||||||||||
(1) | The aggregate intrinsic value is computed based on the closing price of the Companys stock on April 29, 2011. |
No options were granted in the first nine months of fiscal years 2011 or 2010.
The total intrinsic value of options exercised during the nine months ended April 30, 2011 and
2010 was approximately $546,000 and $934,000, respectively.
Performance Shares
On August 1, 2010, there were 197,249 non-vested performance shares outstanding which
reflected the maximum number of shares under the awards. During the nine months ended April 30,
2011, there were no awards vested and there were 103,298 performance-based stock awards granted.
The fair value of the award was measured on the grant date of December 7, 2010 using the Companys
closing stock price of $15.65. Stock-based compensation expense on the award will be recognized on
a straight line basis over the requisite service period beginning on the date of grant through the
end of the measurement period ending July 31, 2013, based on the number of shares expected to vest
at the end of the measurement period. As of April 30, 2011, the non-vested performance-based stock
awards consisted of Series 1 and Series 2 awards granted to certain executives in fiscal years
2011, 2010 and 2009, as summarized below.
Closing Stock | ||||||||||||||||||||||
Maximum | Price | 3-Year | Expected | |||||||||||||||||||
Series | Award | (Fair Value) | Measurement | Percentage of | Shares Expected | |||||||||||||||||
Date of Grant | Award | (Shares) | on Grant Date | Period Ending | Vesting | to Vest | ||||||||||||||||
Fiscal Year 2011 Award |
||||||||||||||||||||||
12/7/2010 |
Series 1 | 61,980 | $ | 15.65 | 07/31/2013 | 36.25% | 22,468 | |||||||||||||||
12/7/2010 |
Series 2 | 41,318 | $ | 15.65 | 07/31/2013 | 0.00% | | |||||||||||||||
103,298 | 22,468 | |||||||||||||||||||||
Fiscal Year 2010 Award |
||||||||||||||||||||||
3/17/2010 |
Series 1 | 63,605 | $ | 15.55 | 07/31/2012 | 47.50% | 30,212 | |||||||||||||||
3/17/2010 |
Series 2 | 42,402 | $ | 15.55 | 07/31/2012 | 20.00% | 8,480 | |||||||||||||||
106,007 | 38,692 | |||||||||||||||||||||
Fiscal Year 2009 Award |
||||||||||||||||||||||
12/02/2008 |
Series 1 | 54,745 | $ | 3.19 | 07/31/2011 | 52.50% | 28,741 | |||||||||||||||
12/02/2008 |
Series 2 | 36,497 | $ | 3.19 | 07/31/2011 | 20.00% | 7,299 | |||||||||||||||
91,242 | 36,040 | |||||||||||||||||||||
Total |
300,547 | 97,200 | ||||||||||||||||||||
Series 1:
Vesting for the Series 1 awards is subject to a performance requirement composed of
certain revenue growth objectives and average annual return on invested capital or equity
objectives measured across a three year period. These objectives are measured quarterly using the
Companys budget, actual results and long-term projections. For the fiscal year 2011, 2010 and 2009
awards the expected percentage of vesting is based on performance through April 30, 2011 and
reflects the percentage of shares projected to vest for the respective awards at the end of their
measurement periods.
Series 2:
Vesting for the Series 2 awards is subject to performance requirements pertaining
to the growth rate in the Companys basic earnings per share over a three year period. The
achievement of performance requirements is measured quarterly using the Companys budget, actual
results and long-term projections. For the fiscal year 2011, 2010 and 2009 awards the expected
percentage of vesting is based on performance through April 30, 2011 and reflects the percentage of
shares projected to vest for the respective awards at the end of their measurement periods.
The weighted-average grant-date fair value of performance awards outstanding at April 30, 2011
and August 1, 2010 was $10.99 and $12.33, respectively.
9
Table of Contents
Time Based Shares
A summary of activity for time-based stock awards for the nine months ended April 30, 2011 is
presented below:
Weighted-Average | ||||||||
Grant-Date | ||||||||
Shares | Fair Value | |||||||
Non-vested on August 1, 2010 |
24,070 | $ | 12.66 | |||||
Granted |
25,977 | 16.95 | ||||||
Vested (1) |
(15,286 | ) | 15.05 | |||||
Forfeited |
| | ||||||
Non-vested on April 30, 2011 |
34,761 | 13.89 | ||||||
(1) | During the nine month period ended April 30, 2011 there were 17,353 shares that vested. However, the number of shares presented in the table as vested was adjusted downward for 2,067 shares that had been granted to non-employee directors in fiscal year 2010, but which did not vest. The number of shares granted was calculated based on the aggregate monetary value of the award divided by the Companys closing stock price on the date of grant. The number of shares that vested at the end of each three month service period over the twelve month service period ending November 30, 2010 was based on the Companys closing stock price at the end of each of the three month periods. |
During the nine months ended April 30, 2011, a grant was made to non-employee directors under
time-based awards whereby each non-employee director will be issued shares having a value of
$50,000 for service as a director for the twelve-month period ending November 30, 2011. Each
non-employee director shall be issued shares in quarterly installments for service as a director in
the preceding three months in an amount equal in value to $12,500 valued on the closing price of
the Companys stock price as of the last trading day of each three month service period ending in
February, May, August and November. The aggregate grant-date fair value of $350,000 for the award
will be recognized on a straight-line basis over the requisite service period beginning on the
grant date, January 24, 2011. The number of shares deemed to have been granted was
20,208 shares, an amount calculated using the Companys closing stock price of $17.32 on that date.
The Company also granted 5,769 time-based shares to certain employees during the nine months
ended April 30, 2011 which vest on July 31, 2013. The fair value of the award of $90,285 was
measured on the date of grant on December 7, 2010, using the Companys closing stock price of
$15.65, and will be recognized on a straight line basis over the requisite service period from
December 7, 2010 through July 31, 2013.
The total fair value of shares vested during the nine months ended April 30, 2011 and 2010 was
approximately $262,000 and $191,000, respectively.
There were 32,091 time-based shares granted during the nine months ended April 30, 2010.
(8) Intangible Assets.
Intangible assets are summarized as follows (in thousands):
April 30, 2011 | July 31, 2010 | |||||||||||||||||||
Original | Accumulated | Carrying | Accumulated | Carrying | ||||||||||||||||
Cost | Amortization | Amount | Amortization | Amount | ||||||||||||||||
Intangible assets subject to amortization: (range of useful life): |
||||||||||||||||||||
Creosote supply contract (10 years) |
$ | 4,000 | $ | (3,889 | ) | $ | 111 | $ | (3,689 | ) | $ | 311 | ||||||||
Animal health trademarks (4-5 years) |
364 | (364 | ) | | (359 | ) | 5 | |||||||||||||
Animal
health product registrations and other related assets (5-20 years) |
6,165 | (1,921 | ) | 4,244 | (1,667 | ) | 4,498 | |||||||||||||
Electronic chemicals-related contracts (3-8 years) |
1,164 | (1,004 | ) | 160 | (844 | ) | 320 | |||||||||||||
Electronic chemicals-related trademarks and patents (10-15 years) |
117 | (34 | ) | 83 | (26 | ) | 91 | |||||||||||||
Electronic chemicalsvalue of product qualifications (5 years) |
1,300 | (281 | ) | 1,019 | (95 | ) | 1,205 | |||||||||||||
Total intangible assets subject to amortization |
$ | 13,110 | $ | (7,493 | ) | 5,617 | $ | (6,680 | ) | 6,430 | ||||||||||
Intangible assets not subject to amortization: |
||||||||||||||||||||
Creosote product registrations |
5,339 | 5,339 | ||||||||||||||||||
Penta product registrations |
8,765 | 8,765 | ||||||||||||||||||
Total intangible assets not subject to amortization |
14,104 | 14,104 | ||||||||||||||||||
Total intangible assets, net |
$ | 19,721 | $ | 20,534 | ||||||||||||||||
Intangible assets subject to amortization are amortized over their estimated useful lives.
Amortization expense was approximately $227,000 and $261,000 for the three month periods ended
April 30, 2011 and 2010 respectively, and was approximately $813,000 and $748,000 for the first
nine months of fiscal years 2010 and 2011, respectively.
10
Table of Contents
(9) Dividends.
Dividends of approximately $283,000 ($0.025 per share) and $224,000 ($0.02 per
share) were declared and paid in the third quarter of fiscal years 2011 and 2010, respectively.
Dividends of approximately $735,000 ($0.065 per share) and $669,000 ($0.06 per share) were declared
and paid in the first nine months of fiscal years 2011 and 2010, respectively.
(10) Comprehensive Income.
The Companys other comprehensive income (loss) includes foreign
currency translation gains and losses which are recognized as accumulated other comprehensive
income (loss) in the consolidated balance sheets. The following table summarizes total
comprehensive income (loss) for the periods indicated (in thousands):
Three Months Ended | Nine Months Ended | |||||||||||||||
April 30, | April 30, | |||||||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||||||
Net income |
$ | 2,607 | $ | 3,342 | $ | 8,547 | $ | 11,925 | ||||||||
Other comprehensive income (loss): |
||||||||||||||||
Net foreign currency translation gain (loss) |
1,869 | (1,080 | ) | 3,050 | (1,426 | ) | ||||||||||
Total comprehensive income |
$ | 4,476 | $ | 2,262 | $ | 11,597 | $ | 10,499 | ||||||||
(11) Segment Information.
The Company operates four reportable segments organized around its
three product lines: electronic chemicals, industrial wood treating chemicals and animal health
products.
The Company previously had five reportable segments, Electronic Chemicals North America,
Electronic Chemicals International, penta, creosote and animal health. During the fourth quarter
of fiscal year 2010 the Company re-evaluated the criteria used to determine operating segments, and
concluded that its electronic chemicals product line met the criteria of a single operating
segment. As a result, the composition of the Companys reportable segments was revised to reflect a
change from five to four reportable segments, electronic chemicals, penta, creosote and animal
health. Prior year information has been reclassified to conform to the current period presentation.
Three Months Ended | Nine Months Ended | |||||||||||||||
April 30, | April 30, | |||||||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||||||
(Amounts in thousands) | ||||||||||||||||
Sales |
||||||||||||||||
Electronic Chemicals |
$ | 38,509 | $ | 29,572 | $ | 111,303 | $ | 75,477 | ||||||||
Penta |
5,597 | 5,734 | 17,343 | 16,784 | ||||||||||||
Creosote |
17,792 | 13,022 | 56,013 | 47,219 | ||||||||||||
Animal Health |
3,176 | 3,286 | 7,455 | 6,682 | ||||||||||||
Total sales for reportable segments |
$ | 65,074 | $ | 51,614 | $ | 192,114 | $ | 146,162 | ||||||||
Depreciation and amortization |
||||||||||||||||
Electronic Chemicals |
$ | 1,435 | $ | 1,153 | $ | 4,308 | $ | 3,007 | ||||||||
Penta |
119 | 149 | 411 | 458 | ||||||||||||
Creosote |
73 | 67 | 219 | 206 | ||||||||||||
Animal Health |
150 | 190 | 535 | 573 | ||||||||||||
Other general corporate |
65 | 66 | 215 | 198 | ||||||||||||
Total consolidated depreciation and amortization |
$ | 1,842 | $ | 1,625 | $ | 5,688 | $ | 4,442 | ||||||||
Segment income (loss) from operations (1) |
||||||||||||||||
Electronic Chemicals |
$ | 1,587 | $ | 2,196 | $ | 5,943 | $ | 5,597 | ||||||||
Penta |
1,647 | 1,607 | 5,276 | 5,428 | ||||||||||||
Creosote |
1,524 | 2,503 | 6,096 | 12,893 | ||||||||||||
Animal Health |
312 | 228 | 59 | (55 | ) | |||||||||||
Total segment income from operations |
$ | 5,070 | $ | 6,534 | $ | 17,374 | $ | 23,863 | ||||||||
April 30, | July 31, | |||||||
2011 | 2010 | |||||||
Assets |
||||||||
Electronic Chemicals |
$ | 118,014 | $ | 109,367 | ||||
Penta |
20,403 | 20,094 | ||||||
Creosote |
17,828 | 21,731 | ||||||
Animal Health |
16,450 | 15,950 | ||||||
Total assets for reportable segments |
$ | 172,695 | $ | 167,142 | ||||
11
Table of Contents
(1) | Segment income (loss) from operations includes allocated corporate overhead expenses. During the first quarter of fiscal year 2011, the Company changed the method it uses to allocate those costs to its reportable segments which is based on segment net sales. As a result prior year amounts have been reclassified to reflect the current year method. Corporate overhead expenses allocated to segment income (loss) for the three and nine months ended April 30, 2011 and 2010 were as follows: |
Three Months Ended | Nine Months Ended | |||||||||||||||
April 30, | April 30, | |||||||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||||||
(Amounts in thousands) | ||||||||||||||||
Electronic Chemicals |
$ | 1,057 | $ | 1,091 | $ | 2,941 | $ | 2,879 | ||||||||
Penta |
199 | 222 | 586 | 586 | ||||||||||||
Creosote |
646 | 615 | 1,834 | 1,623 | ||||||||||||
Animal Health |
129 | 103 | 378 | 273 | ||||||||||||
Total corporate overhead expense allocation |
$ | 2,031 | $ | 2,031 | $ | 5,739 | $ | 5,361 | ||||||||
A reconciliation of total segment information to consolidated amounts is as follows:
April 30, | July 31, | |||||||
2011 | 2010 | |||||||
(Amounts in thousands) | ||||||||
Assets: |
||||||||
Total assets for reportable segments |
$ | 172,695 | $ | 167,142 | ||||
Total assets for discontinued operations (1) |
664 | 739 | ||||||
Cash and cash equivalents |
539 | 3,073 | ||||||
Prepaid and other current assets |
3,598 | 2,174 | ||||||
Other |
3,237 | 2,893 | ||||||
Total assets |
$ | 180,733 | $ | 176,021 | ||||
Three Months Ended | Nine Months Ended | |||||||||||||||
April 30, | April 30, | |||||||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||||||
Sales: |
||||||||||||||||
Total sales for reportable segments |
$ | 65,074 | $ | 51,614 | $ | 192,114 | $ | 146,162 | ||||||||
Net sales |
$ | 65,074 | $ | 51,614 | $ | 192,114 | $ | 146,162 | ||||||||
Segment income from operations: |
||||||||||||||||
Total segment income from operations (2) |
$ | 5,070 | $ | 6,534 | $ | 17,374 | $ | 23,863 | ||||||||
Other corporate expense (2) |
(487 | ) | (702 | ) | (2,425 | ) | (3,157 | ) | ||||||||
Operating income |
4,583 | 5,832 | 14,949 | 20,706 | ||||||||||||
Interest income |
| 3 | 1 | 5 | ||||||||||||
Interest expense |
(571 | ) | (542 | ) | (1,765 | ) | (1,634 | ) | ||||||||
Other income (expense), net |
50 | (69 | ) | (140 | ) | (168 | ) | |||||||||
Income from continuing operations before income taxes |
$ | 4,062 | $ | 5,224 | $ | 13,045 | $ | 18,909 | ||||||||
(1) | Reflects long-term deferred tax assets related to discontinued operations as of April 30, 2011 and July 31, 2010. | |
(2) | Other corporate expense primarily represents employee stock-based compensation expenses and those expenses associated with the companys operation as a public entity such as board compensation, audit expense and fees related to the listing of our stock. Beginning in the first quarter of fiscal year 2011, the Company changed the method it uses to allocate certain corporate overhead costs to its reportable segments, and accordingly prior year amounts have been reclassified to reflect the current year method. |
12
Table of Contents
(12) Long-Term Obligations.
The Companys debt consisted of the following (in thousands):
April 30, | July 31, | |||||||
2011 | 2010 | |||||||
Senior Secured Debt: |
||||||||
Note Purchase Agreement, maturing on December 31, 2014, interest rate of 7.43% |
$ | 20,000 | $ | 20,000 | ||||
Secured Debt: |
||||||||
Term Loan Facility, maturing on December 31, 2012, variable interest rates
based on LIBOR plus 2.00% (2.25% at April 30, 2011) |
13,333 | 19,333 | ||||||
Revolving Loan Facility, maturing on December 31, 2012, variable interest
rates based on LIBOR plus 2.00% (2.25% at April 30, 2011) |
17,907 | 20,000 | ||||||
Total debt |
51,240 | 59,333 | ||||||
Current portion of long-term debt |
(8,000 | ) | (8,000 | ) | ||||
Long-term debt, net of current portion |
$ | 43,240 | $ | 51,333 | ||||
To finance the acquisition of the electronic chemicals business in December 2007, the Company
entered into a credit agreement and a note purchase agreement. The credit facility included a
revolving loan facility of $35.0 million and a term loan facility of $35.0 million. The Company
amended those facilities in March 2010 to increase the amount that may be borrowed under the
revolving loan facility to $50 million. The facility was entered into with Wachovia Bank, National
Association, a subsidiary of Wells Fargo & Co., Bank of America, N.A., The Prudential Insurance
Company of America, and Pruco Life Insurance Company. Advances under the revolving loan and the
term loan mature December 31, 2012. The revolving loan and the term loan each bear interest at
varying rate of LIBOR plus a margin based on our funded debt to earnings before interest, taxes,
depreciation and amortization (EBITDA).
Ratio of Funded Debt to EBITDA | Margin | |||
Equal to or greater than 3.0 to 1.0 |
2.75 | % | ||
Equal to or greater than 2.5 to 1.0, but less than 3.0 to 1.0 |
2.50 | % | ||
Equal to or greater than 2.0 to 1.0, but less than 2.5 to 1.0 |
2.25 | % | ||
Equal to or greater than 1.5 to 1.0, but less than 2.0 to 1.0 |
2.00 | % | ||
Less than 1.5 to 1.0 |
1.75 | % |
Advances outstanding under the revolving loan and the term loan bear interest currently at
2.25% per year (LIBOR plus 2.00%). For the first 24 months of the term facility, principal payments
were $458,333, per month, then, beginning January 2010, principal payments became $666,667 per
month for the balance of the term prior to maturity. The purchase of
the electronic chemical assets from General Chemical on March 29, 2010
was funded with available cash and borrowings on the revolving loan. At April 30, 2011, the amount outstanding on
the revolving loan was $17.9 million and the amount outstanding on the term loan was $13.3 million.
In fiscal year 2008 the Company also entered into a $20.0 million note purchase agreement with
the Prudential Insurance Company of America. Advances under the note purchase agreement mature
December 31, 2014, and bear interest at 7.43% per annum. Principal is payable at maturity. At April
30, 2011, $20.0 million was outstanding under the note purchase agreement.
Loans under the amended and restated credit facility and the note purchase agreement are
secured by the Companys assets, including inventory, accounts receivable, equipment, intangible
assets, and real property. The credit facility and the note purchase agreement have restrictive
covenants, including that the Company must maintain a fixed charge coverage ratio of 1.5 to 1.0,
and maintain a ratio of funded debt to EBITDA of 3.0 to 1.0. The Company is also obligated to
maintain a debt to capitalization ratio of not more than 50%. For purposes of calculating these
financial covenant ratios, we use a pro forma EBITDA. On April 30, 2011, the Company was in
compliance with all of its debt covenants.
(13) Income Taxes.
Income tax expense for the interim periods was computed using the effective
tax rate estimated to be applicable for the full fiscal year. The effective tax rate for the third
quarter and the first nine months of fiscal year 2011 was 34.7% and
33.9%, respectively, which
included the effects of discrete period adjustments recognized during the first and third quarters
of $410,000 and $208,000, respectively. The adjustments were for the reversal of the valuation
allowance related to a foreign subsidiary. As of April 30, 2011, the Company evaluated and concluded that there were no significant uncertain tax positions requiring recognition in the Companys consolidated financial statements.
The Companys subsidiary in Italy is currently under examination for the period ended July 31,
2009. Adjustments were proposed by the taxing authority at the end of April 2011 that would result
in approximately $1.6 million (including interest and penalties) of additional income tax, if all
the adjustments are sustained. The Company is providing additional information in response to the
proposed adjustments, and intends to vigorously defend its tax positions.
The ultimate outcome of this examination is subject to uncertainty and no amount has been recorded in the Companys consolidated financial statements.
13
Table of Contents
(14) Discontinued Operations.
In fiscal year 2008 the Company discontinued operations of its
herbicide product line that had comprised the agricultural chemical segment. During the three and
nine months ended April 30, 2011, there were no sales reported in discontinued operations, and the
Company reported a net loss from discontinued operations of $44,000 and $80,000 from the
dismantling of related equipment which began in the second quarter of fiscal year 2011. No amounts
were recorded for the three and nine months ended April 30, 2010.
(15) Litigation and Other Contingencies.
The Company is subject to contingencies, including
litigation relating to environmental laws and regulations, commercial disputes and other matters.
Certain of these contingencies are discussed below. The ultimate resolution of these contingencies
is subject to significant uncertainty, and should the Company fail to prevail in any of them or
should several of them be resolved against the Company in the same reporting period, these matters
could, individually or in the aggregate, be material to the consolidated financial statements. The
ultimate outcome of these matters, however, cannot be determined at this time, nor can the amount
of any potential loss be reasonably estimated, and as a result no amounts have been recorded in the
Companys consolidated financial statements.
The Company discontinued the operation of its agricultural herbicide product line, referred to
as MSMA, but in connection with that product line it was a member of the MSMA task force. In 2007
Albaugh, Inc. sued an entity related to the MSMA task force, Arsonate Herbicide Products, Limited)
(AHP), claiming that AHP overbilled it for certain task force expenses. The Company had been a
member of the task force with two other companies. Although Albaugh, Inc. had agreed to reimburse
AHP for certain task force expenses for MSMA studies and registration support costs, it claims that
it was overbilled for many years. The case was tried in October 2009 in the U.S. District Court for
the So. District of Iowa, and styled as Albaugh, Inc. vs. Arsonate Herbicide Products, Limited. The
court rendered a judgment on May 6, 2011 against AHP for approximately $945,000, plus interest. The
Company intends to vigorously defend against any attempt to collect the judgment against AHP from
the Company.
A lawsuit was filed against our subsidiary, KMG de Mexico, relating to the title to the land
on which our facility in Matamoros is located. The plaintiffs claim that their title to the land is
superior to the person from whom our subsidiary bought the land. The plaintiffs are seeking to have
our subsidiarys purchase overturned, and to recover the land and certain improvements or their value. The lawsuit was
initially filed in 1998 in Matamoros, Mexico under Adolfo Cazares Rosas, et al vs. KMG de Mexico
and Guillermo Villarreal. In January 2008, the case was sent by the appeals court back to the lower
court to obtain additional factual information, and on April 20, 2009 the plaintiffs were required
to re-file the case in the First Civil Court in Matamoros, Tamaulipas, Mexico as Adolfo Cazares,
Luis Escudero and Juan Cue vs. KMG de Mexico and Guillermo Villarreal.
When it purchased assets from Air Products, Inc. (Air Products) in December 2007, the
Company agreed to be responsible for the applicable sales tax on the personal property that it
purchased. The Colorado Department of Revenue audited the purchase, and in November 2009 issued a
deficiency notice to Air Products for unpaid sales tax on the purchase of approximately $819,000,
before interest and penalties. The Company assumed the defense of the matter as allowed under its
indemnity of Air Products. The issue is whether certain property at the Companys Pueblo, Co facility should be classified as
personal property subject to sales tax, or whether the property should be classified as real
property not subject to tax. The matter is now being reviewed internally at the Colorado Department
of Revenue. If a satisfactory resolution is not reached, the dispute would be subject to
arbitration.
The trustee in the bankruptcy proceeding of a customer of the Company filed an action against
the Company seeking the return of $538,000 in payments allegedly made by the bankrupt in the ninety
(90) days prior to the filing of the bankruptcy petition. The action alleges a right to recovery of
the payments as a preference and under several other legal theories. The action is styled as In re
Spansion, Inc., et al. and Pirinate Consulting Group LLC, Claims Agent for the Chapter 11 Estate of
Spansion, Inc., et al. vs. KMG Electronic Chemicals, Inc., and it was filed February 25, 2011 in
the United States Bankruptcy Court, District of Delaware (Bk. No. 09-10690-KJC; Adv. Proc. No.
11-51094-KJC). The Company has filed a claim for unpaid invoices in the bankruptcy in the amount of
approximately $483,000.
In 2007 the Company was sued in Superior Court, Fulton County, Georgia (Atlanta) styled John
Bailey, et al vs Cleveland G. Meredith et al. The case was consolidated in the Superior Court with
other plaintiffs cases as Thompson et al vs Meredith et al. The plaintiffs are persons living near
the wood treating facility of one of our customers. The plaintiffs complain that emissions from the
wood treating facility caused harm to their property and person, and claim that the Company is also
responsible because it sold wood treating chemicals to the facility. In fiscal year 2010, the trial
court granted a motion for summary judgment, and dismissed the Company from the case. The
plaintiffs have appealed. The appellate court heard oral argument in the case in May 2011, but no
decision has been rendered.
14
Table of Contents
The Company is subject to federal, state, local and foreign laws and regulations and potential
liabilities relating to the protection of the environment and human health and safety including,
among other things, the cleanup of contaminated sites, the treatment, storage and disposal of
wastes, the emission of substances into the air or waterways, and various health and safety
matters. The Company expects to incur substantial costs for ongoing compliance with such laws and
regulations. The Company may also face governmental or third-party claims, or otherwise incur
costs, relating to cleanup of, or for injuries resulting from, contamination at sites associated
with past and present operations. The Company accrues for environmental liabilities when a
determination can be made that they are probable and reasonably estimable.
ITEM 2. | MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
We manufacture, formulate and distribute specialty chemicals globally. We operate businesses
engaged in electronic chemicals, industrial wood treating chemicals and animal health products. Our
electronic chemicals are used in the manufacturing of semiconductors. Our wood preserving
chemicals, pentachlorophenol (penta) and creosote are used by our industrial customers primarily
to extend the useful life of utility poles and railroad crossties. Our animal health products
include biotech feed additives, farm and ranch hygiene products and pesticide products used on
cattle, other livestock and poultry to protect the animals from flies and other pests.
Results of Operations
Three Month and Nine Month Periods Ended April 30, 2011 compared with Three Months and Nine Month Periods
Ended April 30, 2010
Segment Data
Segment data is presented for our four reportable segments for the three and nine month
periods ended April 30, 2011 and 2010. The segment data should be read in conjunction with our
condensed consolidated financial statements and related notes thereto included elsewhere in this
report. We previously had five reportable segments, Electronic Chemicals-North America, Electronic
Chemicals-International, and segments for penta, creosote and animal health. During the fourth
quarter of fiscal year 2010 we re-evaluated the criteria used to determine operating segments, and
we concluded that our electronic chemicals product line met the criteria of a single operating
segment. As a result our reportable segments were revised to reflect a change from five to four
reportable segments, electronic chemicals, penta, creosote and animal health. Prior year
information has been reclassified to conform to the current period presentation.
Three Months Ended | Nine Months Ended | |||||||||||||||
April 30, | April 30, | |||||||||||||||
2011 | 2010 | 2011 | 2010 | |||||||||||||
(Amounts in thousands) | ||||||||||||||||
Sales |
||||||||||||||||
Electronic Chemicals |
$ | 38,509 | $ | 29,572 | $ | 111,303 | $ | 75,477 | ||||||||
Penta |
5,597 | 5,734 | 17,343 | 16,784 | ||||||||||||
Creosote |
17,792 | 13,022 | 56,013 | 47,219 | ||||||||||||
Animal Health |
3,176 | 3,286 | 7,455 | 6,682 | ||||||||||||
Net sales |
$ | 65,074 | $ | 51,614 | $ | 192,114 | $ | 146,162 | ||||||||
Net Sales
Net sales increased $13.5 million, or 26.1%, to $65.1 million in the third quarter of fiscal
year 2011 as compared with $51.6 million for the same period of the prior year. For the nine month
comparison, net sales increased $46.0 million, or 31.4%, to $192.1 million in fiscal year 2011 from
$146.2 million in fiscal year 2010.
In the third quarter of fiscal year 2011, the electronic chemicals segment had net sales of
$38.5 million, an increase of $8.9 million, or 30.2%, as compared to $29.6 million for the prior
year period. For the nine month comparison, net sales in the electronic chemicals segment increased
$35.8 million, or 47.5%, to $111.3 million in fiscal year 2011 from $75.5 million in fiscal year
2010. We had increased sales from our March 2010 acquisition of General Chemicals electronic
chemicals business, and demand recovered in the segment from the effect of the economic downturn in
the semiconductor industry.
15
Table of Contents
Net sales of penta products decreased $137,000, or 2.4%, to $5.6 million in the third quarter
of fiscal year 2011 as compared to $5.7 million for the prior year period. For the nine month
comparison, net sales in the penta segment increased $559,000, or 3.3%, to $17.3 million in fiscal
year 2011 from $16.8 million in fiscal year 2010. The reduction in sales for the three month period
was due to normal fluctuations in sales volume. We benefited from an incremental improvement in
purchases of treated poles by utility companies during the nine month period. Additionally, a
global price increase was implemented during the third fiscal quarter.
Creosote net sales also increased in the third quarter of fiscal year 2011, as compared with
the prior year period, by $4.8 million, or 36.6%, to $17.8 million. For the nine month comparison,
net sales in the creosote segment increased $8.8 million, or 18.6%, to $56.0 million in fiscal year
2011 from $47.2 million in fiscal year 2010. For the three and nine month periods the increase was
due to higher volumes offset in part by lower average prices. Demand by railroads for crossties
treated with creosote eased in 2010 from the high levels of previous years, but demand has been
steadily increasing through fiscal year 2011. Crosstie purchases are expected to continue to
increase, although we experienced a decline in creosote sales volumes in the third fiscal quarter
relative to the second fiscal quarter. Average pricing for creosote for both the quarter and the
nine month period declined because of a shift in product mix and renegotiated pricing following
consolidation of our wood treating customer base. We believe that creosote sales volume will
increase in the remainder of the calendar year as rail tie production rates more closely
approximate tie purchases.
Net sales of animal health pesticides decreased by $110,000, or 3.3%, to $3.2 million in the
third quarter of fiscal year 2011 as compared with $3.3 million in the prior year period. For the
nine month comparison, net sales in the animal health segment increased $773,000, or 11.6%, to $7.5
million in fiscal year 2011 from $6.7 million in fiscal year 2010. The increase was primarily
driven by improvement in demand for pest control in the United States in the food animal sector.
The improvement in market conditions for cattle growers has benefited our nine month sales. Because
we are continuing to add registered products in South America, we see increased animal health sales
in that region. Although we are working to have EPA re-establish appropriate tolerances, pending a
successful conclusion of that effort, sales of our Rabon products in the U.S. may be adversely
affected. Sales of our Rabon products in the U.S. constituted approximately 2% of our fiscal year
2010 consolidated net sales. Seasonal usage of animal health pesticides is dependent upon varying
seasonal patterns, weather conditions and weather-related pressure from pests, as well as customer
marketing programs and requirements. Our revenue from the animal health pesticides segment is
seasonal and weighted to the third and fourth quarters of our fiscal year. Revenues from products
subject to significant seasonal variations represented 5.0% of our fiscal year 2010 revenues.
Gross Profit
Gross profit increased by $1.8 million, or 11.3%, to $17.8 million in the third quarter of
fiscal year 2011 from $16.0 million in the same quarter the prior year. For the nine month
comparison, gross profit increased $2.3 million, or 4.6%, to $53.4 million in fiscal year 2011 from
$51.1 million in fiscal year 2010. Gross profit as a percentage of sales decreased to 27.3% in the
third quarter of fiscal year 2011 from 30.9% in the third quarter of fiscal year 2010, and
decreased to 27.8% for the first nine months of fiscal year 2011 from 34.9% for the prior fiscal
year.
The increase in aggregate gross profit for both the three and nine month periods came from
improved sales in our electronic chemicals segment. As a percentage of sales, however, profit
margins in our electronic chemicals segment were down for the third quarter and for the full nine
months of fiscal year 2011 as compared to the prior year. In our electronic chemicals segment,
margins were impacted in both the third quarter and the nine months period by duplicative costs
associated with the integration of our March 2010 acquisition from General Chemical, and by rising
raw material costs. In connection with the integration, we are shifting operations to our
Hollister, CA and Pueblo, CO facilities, but we have continued to incur expense for contract
manufacturing in Dallas, TX and Bay Point, CA. We expect that duplication will be greatly reduced
by the end of the fiscal year as we complete the transition to Hollister and Pueblo. We implemented
a global price increase that took effect during the third fiscal quarter to address our increased
raw material costs. In our creosote segment, we have experienced increased costs this fiscal year
as compared to the prior year, and a lower average price. At the end of fiscal year 2010 we entered
into a long-term contract to sell creosote to our largest customer following its acquisition of
another of our large customers. Although this arrangement has had the effect of increasing creosote
volume substantially, margins have declined from the unusually high levels experienced in fiscal
year 2010 to what we believe is a more normal level.
Other companies may include certain of the costs that we record in cost of sales as
distribution expenses or selling, general and administrative expenses, and may include certain of
the costs that we record in distribution expenses or selling, general and administrative expenses
as a component of cost of sales, resulting in a lack of comparability between our gross profit and
that reported by other companies.
16
Table of Contents
Distribution Expenses
Distribution expenses are presented as a line item separate from our selling, general and
administrative expenses in the consolidated statements of income. Prior year information has been
reclassified to conform to this presentation.
Distribution expenses increased $2.8 million, or 59.6%, to $7.6 million in the third quarter
of fiscal year 2011 as compared with $4.8 million in the prior year period. For the nine month
comparison, distribution expense increased $7.2 million, or 50.8%, to $21.3 million in fiscal year
2011 from $14.1 million in fiscal year 2010. Distribution expenses were approximately 11.7% and
11.1% of net sales for the third quarter and for the first nine months of fiscal year 2011,
respectively, and 9.2% and 9.7% for the comparable prior year periods.
We recognized an increase in distribution expense in our electronic chemicals segment of
approximately $2.5 million and $6.4 million for the three and nine months ended April 30, 2011,
respectively, as compared to the same prior year periods. About $2.3 million and $5.8 million of
the increase for the three and nine month periods, respectively, as compared to the prior year
periods, was due to increased storage, handling and freight expense, in large part from greater
volume from the General Chemical acquisition. For electronic chemicals, distribution expense was
16.7% of net sales in the third quarter and 16.2% for the nine month period in fiscal year 2011, as
compared to 13.2% and 15.5%, respectively, for the comparable periods in the prior year. The
increase in distribution expense as a percent of sales was due to higher diesel fuel costs, the
impact of our integration effort and additional freight incurred to meet shortage conditions
arising from unscheduled plant outages at two suppliers in the United States. Those suppliers have
now resumed production. Our two wood preservatives segments and our animal health segments had an
aggregate increase of approximately $325,000 and $826,000 in distribution expenses in the third
quarter and first nine months of fiscal year 2011, respectively, mainly because of higher freight
costs and higher volume related railcar cleaning expenses. With increased creosote throughput and
milder temperatures, we expect storage and steaming costs will be down in the remainder of the
fiscal year.
Selling, General and Administrative Expenses
Selling, general, and administrative expenses increased $210,000 to $5.6 million in the third
quarter of fiscal year 2011 from $5.4 million in the same quarter of fiscal year 2010. Those
expenses were 8.6% of sales in the third quarter of fiscal year 2011 and 10.4% of sales in the
third quarter of the prior year. For the nine month comparison, selling, general and administrative
expense increased $903,000, or 5.6%, to $17.1 million in fiscal year 2011 from $16.2 million in
fiscal year 2010.
The increases over the prior year in both the three and nine month periods were primarily for
higher employee costs of approximately $194,000 and $770,000, respectively. The
three month period also included greater third
party integration costs of approximately $20,000, increased expense as compared to the prior year period of $109,000
for permits and licenses, $77,000 for advertising costs and $62,000 for increased insurance. For
the nine month period, we had increased expense of $257,000 for
integration of our acquisition from General Chemical, $82,000 for permits and licenses, $109,000 for
advertising costs and $221,000 for insurance.
Other corporate expense decreased by approximately $215,000 for the three month period and
decreased $732,000 for the nine month period, as compared to the prior year periods. Other
corporate expense primarily represents employee stock-based compensation
expense and those expenses associated with our operation as a public entity such as board
compensation, audit expense and fees related to the listing of our stock. The decrease in the three
month period was due to lower employee stock-based compensation expense of approximately $230,000.
The decrease in the nine month period was primarily due to the fact that we did not incur any
pre-acquisition expense in the current year for our General Chemical acquisition, and because we had
lower key man life insurance expenses of $147,000 and lower employee stock-based compensation expense of $91,000. In the
nine month period of the prior year, we incurred $303,000 for pre-acquisition expense. See Note 11
to the condensed consolidated financial statements.
Interest Expense
Interest expense was $571,000 in the third quarter and $1.8 million in the first nine months
of fiscal year 2011 as compared with $542,000 and $1.6 million in the comparable periods of fiscal
year 2010. The increases were due to greater borrowings on our revolving loan facility to finance
the acquisition of the electronic chemicals business of General Chemical in March 2010.
Income Taxes
Our
effective tax rate was 34.7% and 33.9% in the third quarter and the first nine months,
respectively, of fiscal year 2011, and 36.0% and 36.9% for the respective prior year periods. The
current nine month period income tax expense was net of discrete period adjustments of $410,000 and
$208,000 recognized in the first and third quarters of fiscal year 2011, respectively.
The discrete period adjustments were for the reversal
of the valuation allowance related to a
foreign subsidiary.
17
Table of Contents
Liquidity and Capital Resources
Cash Flows
Net cash provided by operating activities was $10.0 million for the first nine months of
fiscal year 2011 as compared to $10.2 million for the comparable period in 2010. Net income
adjusted for depreciation and amortization increased cash to $14.3 million in the first nine months
of fiscal year 2011. Cash was unfavorably impacted by changes in operating assets including an
increase of $1.1 million in accounts receivable, an increase in prepaid expenses and other assets
of approximately $1.1 million and an increase in inventories of $1.6 million. The increase in
accounts receivable was primarily related to the timing of creosote sales. Prepaid
expense and other assets increased as a result of paying our annual property and casualty insurance
premium. Increased inventories were due to higher inventory amounts in each of our segments, except
for creosote where we saw a reduction in inventory. Cash was also unfavorably impacted by a
decrease in accrued liabilities of $1.0 million, due mainly to a reduction in our employee bonus
accrual.
Net cash used in investing activities in the first nine months of fiscal 2011 was $5.6 million
as compared with $27.9 million in the prior year period. We made additions to property, plant and
equipment of $5.8 million during the first nine months of fiscal year 2011. In the prior year we
purchased the General Chemical business and used $26.7 million from financing activities for that
purpose, and made additions to property of $1.2 million. In the first nine months of fiscal year
2011 we spent approximately $1.3 million in connection with our ongoing expansion project at our
Hollister, CA facility. We also incurred approximately
$3.1 million for capital expenditures at our Pueblo, CO
facility
primarily to implement our consolidation of electronic chemical manufacturing
and for expansion of our bulk delivery fleet to support increased bulk chemical sales. We
also made expenditures of $481,000 for equipment at our Milan, Italy facility. The remaining
capital expenditures were for normal equipment and system upgrades and purchases across our
different locations. The additions to property in the prior year period were also primarily in our
electronic chemicals segment.
Net cash used in financing activities was $8.4 million in the first nine months of fiscal year
2011 as compared to net cash provided by financing activities of $14.8 million in the comparable
prior year period. In the first nine months of fiscal year 2011, we made principal payments of $6.0
million on the term loan indebtedness,
and also had net payments of $2.1 million on our revolving credit
facility. In the first nine months of fiscal year 2010, we made principal payments of $5.0 million
on the term loan indebtedness and had net borrowings of $20.0 million of the revolving credit
facility.
In the nine month periods ended April 30, 2011 and 2010, we paid dividends of $735,000 and
$669,000, respectively. On February 24, 2011, we announced an increase in our quarterly dividend
rate to $0.025 per share from $0.020 per share, a 25% increase. It is our policy to pay dividends
from available cash after taking into consideration our profitability, capital requirements,
financial condition, growth, business opportunities and other factors which our board of directors
may deem relevant, and the increase in the quarterly dividend reflects that analysis.
Working Capital
We have a revolving line of credit under an amended and restated credit agreement. At April
30, 2011, we had $17.9 million outstanding under that revolving facility, and our net borrowing
base availability was $18.6 million. Management believes that our current credit facility, combined
with cash flows from operations, will adequately provide for our working capital needs for current
operations for the next twelve months.
18
Table of Contents
Long Term Obligations
To finance the acquisition of the electronic chemicals business in December 2007, we entered
into a credit agreement and a note purchase agreement with Wachovia Bank, National Association, a
subsidiary of Wells Fargo & Co., Bank of America, N.A., The Prudential Insurance Company of
America, and Pruco Life Insurance Company. The new credit facility included a revolving loan
facility of $35.0 million and a term loan facility of $35.0 million. We amended those facilities in
March 2010 to increase the amount that may be borrowed under the revolving loan facility to $50.0
million. Advances under the revolving loan and the term loan mature December 31, 2012. They each
bear interest at varying rate of LIBOR plus a margin based on our funded debt to EBITDA, as
described below.
Ratio of Funded Debt to EBITDA | Margin | |||
Equal to or greater than 3.0 to 1.0 |
2.75 | % | ||
Equal to or greater than 2.5 to 1.0, but less than 3.0 to 1.0 |
2.50 | % | ||
Equal to or greater than 2.0 to 1.0, but less than 2.5 to 1.0 |
2.25 | % | ||
Equal to or greater than 1.5 to 1.0, but less than 2.0 to 1.0 |
2.00 | % | ||
Less than 1.5 to 1.0 |
1.75 | % |
Advances outstanding under the revolving loan and term loan bear interest currently at 2.25%
per year (LIBOR plus 2.00%). For the first 24 months of the term facility, principal payments were
$458,333 per month, then beginning January 2010 principal payments became $666,667 per month for
the balance of the term prior to maturity. The purchase of the electronic chemicals assets from
General Chemical on March 29, 2010 was funded with available cash and borrowings under the
revolving loan. At April 30, 2011, $17.9 million was outstanding on the revolving facility and
$13.3 million was outstanding on the term loan.
The financing for the acquisition of the electronic chemicals business in fiscal year 2008
included a $20.0 million note purchase agreement with the Prudential Insurance Company of America.
Advances under the note purchase agreement mature December 31, 2014, and bear interest at 7.43% per
annum. Principal is payable at maturity. At April 30, 2011, $20.0 million was outstanding under the
note purchase agreement.
Loans under the amended and restated credit facility and the note purchase agreement are
secured by our assets, including inventory, accounts receivable, equipment, intangible assets and
real property. The credit facility and the note purchase agreement have restrictive covenants,
including that we must maintain a fixed charge coverage ratio of 1.5 to 1.0, and a ratio of funded
debt to EBITDA of 3.0 to 1.0. We are also obligated to maintain a debt to capitalization ratio of
not more than 50%. For purposes of calculating these financial covenant ratios, we use a pro forma
EBITDA. On April 30, 2011, we were in compliance with all of our debt covenants.
Off-Balance Sheet Arrangements
We have no off-balance sheet arrangements, such as financing or unconsolidated variable
interest entities.
Recent Accounting Standards
We have considered all recently issued accounting standards updates and SEC rules and
interpretive releases.
In December 2010, the Financial Accounting Standards Board issued new accounting guidance for
the disclosure of supplementary pro forma information for business combinations. The guidance
clarifies the acquisition date that should be used for reporting the pro forma financial
information disclosures when comparative financial statements are presented and specifies that the
entity should disclose revenue and earnings of the combined entity as though the business
combination(s) that occurred during the current year had occurred as of the beginning of the
comparable prior annual reporting period only. The guidance also expands the supplemental pro forma
disclosure requirements to include a description of the nature and amount of material, non
recurring pro forma adjustments directly attributable to the business combination included in the
reported pro forma information. The new guidance is effective prospectively for business
combinations with an acquisition date on or after the beginning of the first annual reporting
period beginning on or after December 15, 2010. Early adoption is permitted. We do not expect the
new guidance to have a material impact on its consolidated financial statements.
Critical Accounting Policies and Estimates
Our condensed consolidated financial statements are prepared in conformity with accounting
principles generally accepted in the United States of America. The preparation of these condensed
consolidated financial statements requires the use of estimates, judgments, and assumptions that
affect the reported amounts of assets and liabilities at the date of the condensed consolidated
financial statements and the reported amounts of revenues and expenses during the periods
presented. There were no significant changes in our critical accounting policies as described in
our Annual Report on Form 10-K for the fiscal year ended July 31, 2010.
During the second quarter of fiscal year 2011, the Company changed its estimate of the useful
lives of certain equipment purchased in the General Chemical acquisition. This change had the
effect of decreasing depreciation expense by $350,000, and the effect of increasing income from
continuing operations before income taxes by $350,000, increasing net income by $215,000 and increasing basic and
diluted earnings per share by $0.02 for the three month period ended April 30, 2011. For the nine
month period ended April 30, 2011,
this change had the effect of decreasing depreciation expense by $761,000, and the effect of
increasing income from continuing operations before income taxes by $761,000, increasing net income by $470,000 and
increasing basic and diluted earnings per share by $0.04.
19
Table of Contents
Disclosure Regarding Forward Looking Statements
We are including the following discussion to inform our existing and potential security
holders generally of some of the risks and uncertainties that can affect us and to take advantage
of the safe harbor protection for forward-looking statements that applicable federal securities
law affords. From time to time, our management or persons acting on our behalf make forward-looking
statements to inform existing and potential security holders about our company. These
forward-looking statements include information about possible or assumed future results of our
operations. All statements, other than statements of historical facts, included or incorporated by
reference in this report that address activities, events or developments that we expect or
anticipate may occur in the future, including such things as future capital expenditures, business
strategy, competitive strengths, goals, growth of our business and operations, plans and references
to future successes may be considered forward-looking statements. Also, when we use words such as
anticipate, believe, estimate, intend, plan, project, forecast, may, should,
budget, goal, expect, probably or similar expressions, we are making forward-looking
statements. Many risks and uncertainties may impact the matters addressed in these forward-looking
statements. Our forward-looking statements speak only as of the date made and we will not update
forward-looking statements unless the securities laws require us to do so.
Some of the key factors which could cause our future financial results and performance to vary
from those expected include:
| the loss of primary customers; |
| our ability to implement productivity improvements, cost reduction initiatives or facilities expansions; |
| market developments affecting, and other changes in, the demand for our products and the entry of new competitors or the introduction of new competing products; |
| availability or increases in the price of our primary raw materials or active ingredients; |
| the timing of planned capital expenditures; |
| our ability to identify, develop or acquire, and market additional product lines and businesses necessary to implement our business strategy and our ability to finance such acquisitions and development; |
| the condition of the capital markets generally, which will be affected by interest rates, foreign currency fluctuations and general economic conditions; |
| cost and other effects of legal and administrative proceedings, settlements, investigations and claims, including environmental liabilities which may not be covered by indemnity or insurance; |
| the effects of weather, earthquakes, other natural disasters and terrorist attacks; |
| the ability to obtain registration and re-registration of our products under applicable law; |
| the political and economic climate in the foreign or domestic jurisdictions in which we conduct business; and |
| other United States or foreign regulatory or legislative developments which affect the demand for our products generally or increase the environmental compliance cost for our products or impose liabilities on the manufacturers and distributors of such products. |
The information contained in this report, including the information set forth under the
heading Risk Factors, identifies additional factors that could cause our results or performance
to differ materially from those we express in our forward-looking statements. Although we believe
that the assumptions underlying our forward-looking statements are reasonable, any of these
assumptions and, therefore, the forward-looking statements based on these assumptions, could
themselves prove to be inaccurate. In light of the significant uncertainties inherent in the
forward-looking statements which are included in this report and the exhibits and other
documents incorporated herein by reference, our inclusion of this information is not a
representation by us or any other person that our objectives and plans will be achieved.
20
Table of Contents
ITEM 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK |
We are exposed to certain market risks in the ordinary course of our business, arising
primarily from changes in interest rates and to a lesser extent foreign currency exchange rate
fluctuations. Generally we do not utilize derivative financial instruments or hedging transactions
to manage that risk.
Interest Rate Sensitivity
As of April 30, 2011 our fixed rate debt consisted of $20.0 million of term notes with an
interest rate of 7.43%, maturing on December 31, 2014.
As of April 30, 2011 our variable rate debt consisted of a credit facility with an interest
rate of LIBOR plus 2.00%, maturing on December 31, 2012. On April 30, 2011, we had $17.9 million
borrowed on our $50.0 million revolving credit line under that facility, and $13.3 million borrowed
on a term loan under that same facility. Principal payments on the term loan were $458,333 per
month for the first two years of the term facility and now are $666,667 per month for the remaining
term of the facility.
Based on the outstanding balance of our variable rate debt and the LIBOR rate as of April 30,
2011, taking into account planned principal reductions a 1.0% change in the interest rate would
result in a change of approximately $182,000 in interest expense for the next twelve months.
Foreign Currency Exchange Rate Sensitivity
We are exposed to fluctuations in foreign currency exchange rates from the international
operations of our electronic chemicals segment. Those international operations are centered in
Europe and use the Euro as their functional currency, rather than the U.S. Dollar which is our
consolidated reporting currency. Currency translation gains and losses result from the process of
translating the segments financial statements from its functional currency into our reporting
currency. Currency translation gains and losses have no impact on the consolidated statements of
income and are recorded as other comprehensive income (loss) within stockholders equity in our
consolidated balance sheets. Assets and liabilities have been translated using exchange rates in
effect at the balance sheet dates. Revenues and expenses have been translated using the average
exchange rates during the period.
During the nine months ended April 30, 2011, we recognized foreign currency translation gains
of $3.1 million as other comprehensive income in the consolidated balance sheets. At April 30,
2011, the cumulative foreign currency translation loss reflected in accumulated other comprehensive
loss was $285,000.
Additionally we have limited exposure to certain transactions denominated in a currency other
than the functional currency in our Italy operations. Accordingly, we recognize exchange gains or
losses in our consolidated statement of operations from these transactions. We believe the impact
of changes in foreign currency exchange rates does not have a material effect on our results of
operations or cash flows.
ITEM 4. | CONTROLS AND PROCEDURES |
The term disclosure controls and procedures is defined in Rules 13a-15(e) and 15d-15(e) of
the Securities Exchange Act of 1934. This term refers to the controls and procedures of a company
that are designed to ensure that information required to be disclosed by a company in the reports
that it files or submits under the Exchange Act is recorded, processed, summarized and reported
within the time periods specified by the Securities and Exchange Commission. Our management,
including our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness
of our disclosure controls and procedures as of the end of the period covered by this report. Based
upon that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that
our disclosure controls and procedures were effective as of the end of the period covered by this
report.
There were no changes to our internal control over financial reporting during the quarterly
period covered by this Report on Form 10-Q that have materially affected, or are reasonably likely
to materially affect, our internal control over financial reporting.
21
Table of Contents
PART II OTHER INFORMATION
ITEM 1. | LEGAL PROCEEDINGS |
The information set forth in note 15 to the condensed consolidated financial statements
included in Item 1 of Part I of this report is incorporated herein by reference.
ITEM 1A. | RISK FACTORS |
There have been no material changes to the risk factors contained in our Annual Report on Form
10-K for the fiscal year ended July 31, 2010.
ITEM 2. | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS |
Not applicable.
ITEM 3. | DEFAULTS UPON SENIOR SECURITIES |
Not applicable.
ITEM 4. | REMOVED AND RESERVED |
ITEM 5. | OTHER INFORMATION |
The Nominating and Corporate Governance Committee will consider recommendations for directors
made by shareholders for fiscal year 2012, if such recommendations are received in writing,
addressed to the chair of the committee, Mr. Urbanowski, in care of the Company, at 9555 W. Sam
Houston Parkway S., Suite 600, Houston, Texas 77099 by July 2, 2011.
ITEM 6. | EXHIBITS |
The financial statements are filed as part of this report in Part 1, Item 1. The following
documents are filed as exhibits. Documents marked with an asterisk (*) are management contracts or
compensatory plans, and portions of documents marked with a dagger () have been granted
confidential treatment.
31.1 | Certificates under Section 302 the Sarbanes-Oxley Act of 2002 of the Chief Executive Officer. |
|||
31.2 | Certificates under Section 302 the Sarbanes-Oxley Act of 2002 of the Chief Financial Officer. |
|||
32.1 | Certificates under Section 906 of the Sarbanes-Oxley Act of 2002 of the Chief Executive Officer. |
|||
32.2 | Certificates under Section 906 of the Sarbanes-Oxley Act of 2002 of the Chief Financial Officer. |
22
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly
caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
KMG Chemicals, Inc. | ||||
By:
|
/s/ J. Neal Butler
|
Date: June 9, 2011 | ||
President and Chief Executive Officer | ||||
By:
|
/s/ John V. Sobchak
|
Date: June 9, 2011 | ||
Vice President and Chief Financial Officer |
23